ACE Inhibitors Market Report 2026

ACE Inhibitors Market Overview

• ACE Inhibitors market size has reached to $7.41 billion in 2025 • Expected to grow to $10.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Incidence Of Cardiac Disorders Fuels Growth In The ACE Inhibitors Market • Market Trend: Advancement In Blood Pressure Control Generic ACE Inhibitor With Diuretic Launched • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under ACE Inhibitors Market?

ACE inhibitors, also known as angiotensin-converting enzyme (ACE) inhibitors, refer to a type of medication used to treat and manage hypertension. They function by stopping the body's enzyme from generating angiotensin II, a chemical that constricts blood vessels and raises blood pressure. Its basic function is to relax the veins and arteries to reduce blood pressure. The main types of ACE inhibitors are sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are chemical compounds that possess a sulfhydryl group (-SH) within their structure. The several types of drugs included are ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others, which are available in various forms of dosage, including oral tablets and oral solutions. These are used in several applications, such as heart failure, chronic kidney disease, hypertension, diabetes, heart attack, and others, and are used by various end-users, including hospitals, online drug stores, and others.

What Is The ACE Inhibitors Market Growth Forecast?

The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $10.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for personalized medicine, integration of digital health solutions, expansion of emerging markets, development of novel ace inhibitor combinations, growth in home healthcare services. Major trends in the forecast period include personalized hypertension management, telemedicine & remote patient monitoring, combination therapy development, rise in generic ace inhibitors, expansion of home healthcare solutions.

Global ACE Inhibitors Market Segmentation

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents 2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs 3) By Dosage Form: Oral Tablets, Oral Solutions 4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications 5) By End-Users: Hospitals, Online Drug Stores, Other End-Users Subsegments: 1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril 2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril 3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium

What Is The Driver Of The ACE Inhibitors Market?

An increase in the incidence of cardiac disorders is expected to propel the growth of the ACE inhibitors market going forward. Cardiac disorders refer to a group of medical conditions that affect the heart or blood vessels. These disorders encompass a wide range of conditions, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a crucial role in the management of cardiac disorders by inhibiting the angiotensin-converting enzyme, thereby reducing vasoconstriction, sodium retention, and aldosterone secretion, leading to improved cardiac function. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, an increase in the incidence of cardiac disorders is driving the growth of the ACE inhibitors industry.

Key Players In The Global ACE Inhibitors Market

Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Global ACE Inhibitors Market Trends and Insights

Major companies operating in the ACE inhibitor market are increasing their focus on introducing generic drugs to gain a competitive edge in the market. A generic drug is a medication that has the same active ingredients, dosage, safety, strength, route of administration, and effectiveness as a brand-name drug but is typically sold at a lower cost once the original patent expires. For instance, in August 2023, Pharmascience Inc., a Canada-based pharmaceutical company, launched pms-PERINDOPRIL-INDAPAMIDE, a generic medication formulated for the initial treatment of mild to moderate essential hypertension (high blood pressure) in adults. This combination product includes two active ingredients: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor that aids in relaxing blood vessels, and indapamide, a chlorosulphamoyl diuretic that facilitates the removal of excess fluid and sodium from the body. Together, these ingredients work in synergy to effectively lower blood pressure in a diverse range of patients. pms-PERINDOPRIL-INDAPAMIDE is offered in various dosage forms, including 2 mg, 4 mg, and 8 mg of perindopril erbumine, paired with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.

What Are Latest Mergers And Acquisitions In The ACE Inhibitors Market?

In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. The acquisition is expected to help AstraZeneca expand its product line of aldosterone synthase inhibitors (ASI) for blood pressure lowering in treatment-resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, focuses on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

Regional Insights

North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the ACE Inhibitors Market?

The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the ACE Inhibitors Market Report 2026?

The ace inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ace inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.